Anzeige
Mehr »
Montag, 30.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JAZX | ISIN: SE0006371126 | Ticker-Symbol: 7V3
Frankfurt
27.06.25 | 08:07
0,081 Euro
-3,35 % -0,003
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CANTARGIA AB Chart 1 Jahr
5-Tage-Chart
CANTARGIA AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,0980,13729.06.

Aktuelle News zur CANTARGIA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
CANTARGIA Aktie jetzt für 0€ handeln
17.06.Cantargia Signs SEK 50 Million Financing Facility Agreement, Extending Cash Runway Into 2026 and Providing Operating Flexibility to Drive Strategic Plans255LUND, SE / ACCESS Newswire / June 17, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced that it has entered into a loan agreement of SEK 50 million...
► Artikel lesen
17.06.Cantargia Q1 2025 slides: CAN10 advances amid funding challenges3
11.06.Cantargia's Nadunolimab Aantibody Awarded US FDA Fast Track Designation648Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further development...
► Artikel lesen
11.06.Cantargia AB: Cantargia's nadunolimab antibody awarded US FDA Fast Track Designation306Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further development...
► Artikel lesen
19.05.Cantargia Publishes Promising Preclinical Results Highlighting CAN10's Potential to Inhibit Vascular Inflammation205IL1RAP expression positively correlates with inflammatory markers in human atherosclerotic plaques.IL1RAP blocking antibodies inhibit endothelial activation and neutrophil adhesion induced by IL-1,...
► Artikel lesen
15.05.Bulletin from the Annual General Meeting in Cantargia AB271LUND, SWEDEN / ACCESS Newswire / May 15, 2025 / The Annual General Meeting of Cantargia (STO:CANTA) on May 15, 2025 resolved in accordance with the following:That no dividend would be paid.To discharge...
► Artikel lesen
13.05.Cantargia Publishes Interim Report for the First Quarter of 2025403LUND, SE / ACCESS Newswire / May 13, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced its interim report for the first quarter of 2025."The first...
► Artikel lesen
12.05.Cantargia Announces Successful Phase 1 Results: PK/PD Data of Subcutaneously Administered CAN10 Confirms Every 4-Week Dosing Choice in Phase 2210LUND, SE / ACCESS Newswire / May 12, 2025 / Cantargia (STO:CANTA)Pharmacokinetic (PK) model generated based on the single ascending dose (SAD) data and the first multiple ascending dose (MAD) cohort.Model...
► Artikel lesen
06.05.Cantargia's Announces Publication of Clinical Data Demonstrating Potential of Nadunolimab Plus Pembrolizumab in Solid Tumors234LUND, SE / ACCESS Newswire / May 6, 2025 / Cantargia (STO:CANTA)Results published in the peer-reviewed journal Investigational New DrugsStudy in heavily pre-treated patients with solid tumor indications...
► Artikel lesen
29.04.Invitation to the Presentation of Cantargia's Interim Report for Q1 2025217LUND, SE / ACCESS Newswire / April 29, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) will publish the company's interim report for the first quarter of 2025...
► Artikel lesen
29.04.Cantargia Announces Selection of Treatment Resistant Atopic Dermatitis as Second Target Indication for CAN10191LUND, SE / ACCESS Newswire / April 29, 2025 / Cantargia (STO:CANTA)Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment optionsCAN10 targets...
► Artikel lesen
28.04.Cantargia Announces the Publication of Preclinical Data Highlighting Nadunolimab's Potential to Counteract Tumor-Driven Systemic Immunosuppression104LUND, SE / ACCESS Newswire / April 28, 2025 / Cantargia (STO:CANTA)Preclinical data shows IL1 family signals mediate systemic immune suppression.Blocking IL1RAP can overcome resistance to immune therapy...
► Artikel lesen
25.04.Cantargia Presents Promising Preclinical Results on Anti-IL1RAP Antibody-Drug Conjugate at a Major Cancer Conference412Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical modelsAnti-IL1RAP ADC targets IL1RAP, which is overexpressed in many tumors and their tumor microenvironment...
► Artikel lesen
25.04.Cantargia Presents Association Between Nadunolimab and Reduction of Chemotherapy Induced Peripheral Neuropathy at AACR352LUND, SE / ACCESS Newswire / April 25, 2025 / Cantargia (STO:CANTA)Clinical findings show association between nadunolimab and lower incidence and later onset of CIPNPreclinical data show prevention...
► Artikel lesen
11.04.Cantargia Publishes Annual Report 2024294LUND, SE / ACCESS Newswire / April 11, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced that the annual report for 2024 has been published. The...
► Artikel lesen
11.04.Notice of Annual General Meeting in Cantargia AB269LUND, SE / ACCESS Newswire / April 11, 2025 / Cantargia (STO:CANTA) - The shareholders of Cantargia AB (publ) are invited to the annual general meeting on Thursday, 15 May 2025, at 15.00 CEST at Ideon...
► Artikel lesen
01.04.Cantargia appoints Morten Lind Jensen as Chief Medical Officer234LUNDE, SE / ACCESS Newswire / April 1, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced the appointment of Morten Lind Jensen, MD, PhD, as Chief...
► Artikel lesen
25.03.Cantargia Publishes An Abstract On Parallel Anti-Tumor Activity And Reduction Of Chemotherapy-Induced Neuropathy With Nadunolimab468LUND, SWEDEN / ACCESS Newswire / March 25, 2025 / Cantargia (STO:CANTA)Nadunolimab's additional potential in mitigating neuropathy demonstrated by data from Cantargia's CESTAFOUR and CAPAFOUR clinical...
► Artikel lesen
25.03.Cantargia Presents Promising Preclinical Results on a Novel IL1RAP-Targeting Antibody-Drug Conjugate at AACR 2025322LUND, SE / ACCESS Newswire / March 25, 2025 / Cantargia (STO:CANTA) Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced an upcoming presentation of preclinical data on the development...
► Artikel lesen
13.03.Cantargia to Participate at Van Lanschot Kempen's Life Sciences Conference510LUND, SE / ACCESS Newswire / March 13, 2025 / Cantargia (STO:CANTA) Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that members of Cantargia's management will participate...
► Artikel lesen
Weiter >>
55 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1